The role of estrogens in the prevention of cardiovascular disease is currently of particular interest. Recently, Wenger1 reviewed various randomized clinical trials to assess the effect of hormone replacement therapy in cardiovascular disease and concluded that postmenopausal hormone therapy does not prevent clinical cardiovascular events in healthy women or women with heart disease. The questi...

Cardiovascular disease is the leading cause of death in postmenopausal US women. The contribution of postmenopausal hormone replacement therapy to cardiovascular risk is one of the most controversial women's health topics. Strikingly discordant results, between observational and randomized clinical trials, have been reported. Remaining questions regarding time of hormone therapy initiation are ...

Hormonal substitution therapy has been extremely successful, with respect to morbidity and mortality, in the treatment of the major syndromes of endocrine insufficiency. However, many patients treated for endocrine insufficiencies still suffer from more or less vague complaints and a decreased quality of life. It is likely that these complaints are, at least in part, caused by intrinsic imperfe...

Hormone replacement therapy involves restoring estrogen (female hormone) to body when levels are diminished. Menopause is the most common cause of low estrogen levels. During menopause ovaries (glands that produce eggs and hormones) stop producing estrogen and body no longer menstruate. Women who have had their ovaries surgically removed have decreased levels of estrogen and experience the same...

Severe GH deficiency (GHD) in adults has been described as a clinical entity. However, some of the features associated with GHD could be due to unphysiological and inadequate replacement of other pituitary hormone deficiencies. This may be true for glucocorticoid replacement that lacks a biomarker making dose titration and monitoring difficult. Moreover, oral estrogen replacement therapy decrea...

OBJECTIVE The purpose of the present study was to evaluate the hormonal profile of patients of postmenopausal age during estrogen replacement therapy (ERT) with special reference to the serum levels of biologically active FSH (B-FSH) in a self-adjusted ERT model. DESIGN The hormonal values found have been correlated to climateric symptoms reported by the patients (scored by the Kupperman meno...

Introduction: Obesity and visceral fat accumulation after menopause are associated with insulin resistance and cardiovascular diseases. We investigated the interactive effect of aerobic-resistance training and estrogen replacement therapy on visceral fat, omentin-1 and HOMA-IR in ovariectomized rats. Materials and Methods: Fifty female Wistar rats were ovariectomized (OVX) and divided into 5 gr...

introduction: obesity and visceral fat accumulation after menopause are associated with insulin resistance and cardiovascular diseases. we investigated the interactive effect of aerobic-resistance training and estrogen replacement therapy on visceral fat, omentin-1 and homa-ir in ovariectomized rats. materials and methods: fifty female wistar rats were ovariectomized (ovx) and divided into 5 gr...

Journal of Family Planning and Reproductive Health Care 2004: 30(1) 11 Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104: 499–503. 12 Shumaker SA, Legault C, Rapp SR, et al Estrogen plus progestin and the incidence of dementia and mild cognitive imp...